Across a range of conditions that disproportionately affect women, research into mifepristone’s potential has been slowed, defunded or blocked altogether. Nowhere is that clearer than in the treatment of endometriosis and other serious illnesses that leave millions of women in chronic pain.
Endometriosis—when endometrium cells grow outside the uterus—afflicts an estimated 10 percent of reproductive-age women. It can lead to chronic pelvic and back pain, heavy or abnormal bleeding, pain during sex or bowel movements, fatigue, bloating, digestive issues, infertility, anxiety and depression.
Mifepristone can help—it blocks the progesterone causing the cellular growth and decreases the size of existing endometrial lesions, thereby relieving painful symptoms. But antiabortion politics have obstructed the development of the medication for these uses in the U.S.
Researchers have also produced studies showing mifepristone is effective for treating ovarian and breast cancer, chronic inflammatory diseases, and several psychiatric disorders, including major depressive disorder, post-traumatic stress disorder (PTSD) and psychotic depression.
This is Part 2 of 3 in a new series, “The Moral Property of Women: How Antiabortion Politics Are Withholding Medical Care,” a serialized version of the Winter 2026 print feature article.











